No, Do Not Hold Losartan for Hypokalemia
Losartan should be continued in patients with hypokalemia, as hypokalemia is not a contraindication to ARB therapy and may actually represent an indication to maintain or increase the dose. In fact, losartan can help prevent hypokalemia, which is associated with worse cardiovascular outcomes than hyperkalemia in patients with heart failure.
Key Evidence Supporting Continuation
The FDA label for losartan specifically addresses hyperkalemia as the electrolyte concern requiring monitoring and potential dose adjustment—not hypokalemia 1. The warning states to "monitor serum potassium periodically" with dosage reduction or discontinuation only if hyperkalemia develops 1.
Recent high-quality evidence from the HEAAL trial analysis demonstrates that hypokalemia (≤3.5 mmol/L) was associated with significantly worse outcomes including:
- 58% increased risk of cardiovascular death or heart failure hospitalization (HR 1.58)
- 68% increased risk of all-cause death (HR 1.68)
- 74% increased risk of sudden cardiac death (HR 1.74)
In contrast, hyperkalemia showed no association with these adverse outcomes 2.
Clinical Algorithm
If patient has hypokalemia while on losartan:
Continue losartan - it is protective, not causative
Identify the actual cause of hypokalemia:
- Thiazide or loop diuretics (most common culprit)
- Inadequate dietary potassium intake
- GI losses or other medications
Address the underlying cause:
- If on hydrochlorothiazide: Consider switching to a fixed-dose combination with a potassium-sparing agent, which reduces hypokalaemia risk by 68% (adjusted OR 0.32) 3
- Supplement potassium as needed
- Optimize dietary intake
Consider increasing losartan dose if not at target: Higher-dose losartan (150 mg) actually reduced the risk of hypokalemia by 23% (HR 0.77) compared to low-dose (50 mg) in heart failure patients 2
Common Pitfall to Avoid
Do not discontinue RAAS inhibitors like losartan when encountering hypokalemia. The 2018 ACC/AHA guidelines list hypokalemia as a monitoring parameter for thiazide diuretics, not ARBs 4. The European consensus on hyperkalaemia management emphasizes that RAASi therapy should be maintained at guideline-recommended doses, with potassium-lowering strategies employed when needed rather than stopping these life-saving medications 5.
The evidence consistently shows that hypokalemia poses greater cardiovascular risk than hyperkalemia, and losartan provides protective effects across the full spectrum of potassium levels 2. Stopping losartan for hypokalemia would remove a beneficial medication while failing to address the true cause of the electrolyte disturbance.